Expansion of Cardeation Capital will bring pioneering health care products for heart disease and stroke patients
Cardiovascular disease (CVD) is the leading cause of death globally responsible for 17 million deaths every year and its toll is expected to rise to over 23 million deaths annually by 2030. CVD also represents a major economic burden with the annual economic cost of CVD estimated to range over $500 billion in the United States alone.
The current rapid pace of innovation is helping to reverse these crippling statistics and the health care industry has seen continual growth in Venture Capital investments.
To spur that momentum, the American Heart Association and Phillips, announce the expansion of Cardeation Capital with the first closing on the newest fund, Cardeation II, on June 30. We welcome Research Corporation Technologies, Inc. as our newest collaborator to help bri...